Metraipolis › archive › dc_afdb2fc4b88d

CRISPR and Fanzor in sickle cell disease: current progress and future prospects — Europe PMC PMID:42273255

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42273255
DOI
10.3389/fgeed.2026.1774014
License (as archived)
solo-consultazione
Archived
2026-11-01T07:09:36.230Z
SHA-256 of the archived text
af915cb5ad08f2d59b583045ecd0719af586271a1dbd6293c956903227d855fd
Stable URL of this page
https://metraipolis.com/documento/dc_afdb2fc4b88d

How to cite

CRISPR and Fanzor in sickle cell disease: current progress and future prospects — Europe PMC PMID:42273255 — Europe PMC (en), https://europepmc.org/article/MED/42273255 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_afdb2fc4b88d (Metraipolis archive dc_afdb2fc4b88d, sha256 af915cb5ad08f2d59b583045ecd0719af586271a1dbd6293c956903227d855fd)
BibTeX
@misc{dcafdb2fc4b88d,
  title = {CRISPR and Fanzor in sickle cell disease: current progress and future prospects — Europe PMC PMID:42273255},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42273255},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_afdb2fc4b88d; sha256 af915cb5ad08f2d59b583045ecd0719af586271a1dbd6293c956903227d855fd},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42273255. Agents can read the archived copy with the MCP tool read_document.